Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256415 | 0.86 | LMNA (0.50) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL5256419 | 0.86 | LMNA (0.50) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL19731335 | 0.85 | LMNA (0.49) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL19879735 | 0.85 | LMNA (0.49) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL484670 | 0.85 | LMNA (0.49) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL4987306 | 0.84 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26712747 | 0.83 | LMNA (0.48) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL30296784 | 0.83 | LMNA (0.48) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL517538 | 0.83 | CA12 (0.61) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL4997420 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3747862-A1 | ALDH2 ACTIVATOR | Eisai R&D Management Co., Ltd. (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-10406126-B2 | ALDH2 activator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190231720-A1 | ALDH2 ACTIVATOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| EP-1853600-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10406126-B2 | ALDH2 activator | ALDH2, ALDH1A1, ALDH3A1 | LMNA 4116/4885SMN1; SMN2 1715/4885CA12 854/4885 |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | CDK1, CDK3, CDK2 | LMNA 1168/4885SMN1; SMN2 1486/4885CA12 3325/4885 |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | LMNA 367/4885SMN1; SMN2 3655/4885CA12 4108/4885 |
| US-20190231720-A1 | ALDH2 ACTIVATOR | ALDH2, ALDH1A1, ALDH3A1 | LMNA 4116/4885SMN1; SMN2 1715/4885CA12 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.